CORIN (Corin, Serine Peptidase)

Additionally, Corin treatment upregulated FDX1 expression to trigger Cuproptosis, which suppressed HCC proliferation. Conclusively, Corin possesses potential application as a novel and effective therapeutic option for HCC that simultaneously inhibits KDM1A and HDAC1 expression.

Obstructive fibrinous tracheal pseudomembrane, a rare condition, causes upper airway obstruction within days after extubation. Preoxygenation with high-flow nasal cannula oxygen therapy, followed by coring the pseudomembrane out with an intubation tube, may be an effective, rapid, and minimally invasive means of treatment in selected patients with a subglottic, obstructive, fibrinous tracheal pseudomembrane.

The in vitro tumor-promoting potency of CORIN could be antagonized by selective inhibitors targeting the ERK1/2 MAPK pathway. In conclusion, CORIN is a potential prognostic marker and therapeutic target for GC patients, which may promote tumor progression by mediating the ERK1/2 MAPK signaling pathway and EMT in GC cells.

In DB-04, the efficacy of T-DXd over chemotherapy of physician's choice was consistent, regardless of the characteristics of the sample used (primary or metastatic, archival, or newly collected, biopsy or excision/resection). These results demonstrate that PATHWAY HER2 (4B5) is precise and reproducible for scoring HER2-low status and can be used with multiple breast cancer sample types for reliably identifying patients whose tumors have HER2-low expression and are likely to derive clinical benefit from T-DXd.

P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Oct 2024

P=N/A; Our findings support that the SP142 and 22C3 IHC assays, with their respective clinically applied scoring algorithms, are not analytically equivalent where they identify partially non-overlapping subpopulations of TNBC patients and cannot be substituted with one another regarding PD-L1 detection. Trial registration The Swedish Cancerome Analysis Network - Breast (SCAN-B) study, retrospectively registered 2nd Dec 2014 at ClinicalTrials.gov; ID NCT02306096.

P2, N=40, Recruiting, Cedars-Sinai Medical Center | Trial primary completion date: Sep 2023 --> Dec 2023

P=N/A, N=88, Recruiting, Lawson Health Research Institute | Trial primary completion date: Dec 2024 --> Dec 2025

P=N/A, N=80, Active, not recruiting, Linkoeping University | Trial completion date: Jun 2024 --> Dec 2026 | Trial primary completion date: Apr 2023 --> Dec 2024

P=N/A, N=46, Recruiting, Ain Shams University

ChatGPT failed to consistently generate accurate and comprehensive responses to the majority of radiation oncology patient centered questions, particularly across less common cancers and with "negative control" questions that included incorrect assumptions. This raises concern for the possible ChatGPT mediated reinforcement of patient misperceptions regarding radiotherapy.

Higher levels of inflammation-related exposures were associated with decreased EOC OS among Black women.